Litigation Details for Silbersher v. Allergan plc (N.D. Cal. 2018)

Silbersher v. Allergan plc (N.D. Cal. 2018)

Docket		Date Filed	2018-05-22
Court	District Court, N.D. California	Date Terminated	2023-03-20
Cause	31:3729 False Claims Act	Assigned To	Joseph Spero
Jury Demand	Plaintiff	Referred To
Parties	STATE OF NEW MEXICO
Patents	7,504,509; 8,039,009; 8,058,291; 8,168,209; 8,173,708; 8,283,379; 8,293,794; 8,329,752; 8,338,485; 8,338,486; 8,362,085; 8,580,858; 8,598,233
Attorneys	V. Chai Oliver Prentice
Firms	Gibson, Dunn & Crutcher LLP
Link to Docket	External link to docket

Details for Silbersher v. Allergan plc (N.D. Cal. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-22				External link to document
2018-05-22	135	Order on Motion to Dismiss	Relator relies is a single patent, U.S. Patent No. 8,039,009 (“the ’009 patent”). Id. ¶ 91. Relator … The first category of patents is the Went Patents, a group of eleven patents that list Dr. … 6 The parent patent for all of the Went Patents is the ’291 patent, which was issued on … The Went Patents are U.S. Patent Nos. 8,058,291 (“the ’291 patent”); 8,168,209, as …corrected (“the ’209 patent”); 8,173,708 (“the ’708 patent”); 8,283,379 (“the ’379 patent”);	External link to document
2018-05-22	194	Order on Motion to Dismiss	Relator relies is a single patent, U.S. Patent No. 8,039,009 (“the ’009 patent”). Id. ¶ 91. Relator … The first category of patents is the Went Patents, a group of eleven patents that list Dr. … 9 The parent patent for all of the Went Patents is the ’291 patent, which was issued on … The Went Patents are U.S. Patent Nos. 8,058,291 (“the ’291 patent”); 8,168,209, as …corrected (“the ’209 patent”); 8,173,708 (“the ’708 patent”); 8,283,379 (“the ’379 patent”);	External link to document
2018-05-22	197	Order	Relator relies is a single patent, U.S. Patent No. 8,039,009 (“the ’009 patent”). Id. ¶ 91. Relator … The first category of patents is the Went Patents, a group of eleven patents that list Dr. … 19 The parent patent for all of the Went Patents is the ’291 patent, which was issued on … The Went Patents are U.S. Patent Nos. 8,058,291 (“the ’291 patent”); 8,168,209, as …corrected (“the ’209 patent”); 8,173,708 (“the ’708 patent”); 8,283,379 (“the ’379 patent”);	External link to document
2018-05-22	63	Motion to Dismiss	Went 18 patents (U.S. Patent No. 8,362,085) on anticipation and obviousness … allegations about the remaining patents (the so-called “Went patents”) fail as 11 to the… 27 push-and-pull of the patent system. Resolution of complex patent validity and enforceability issues… • ’009 Patent. Relator also alleges that, in connection with a separate patent, Forest Labs …refers to a ’703 patent in multiple places, but concedes that that patent “has not blocked	External link to document
2018-05-22	68	Dismiss	eleven Went Patents. AC ¶ 58. In addition, the Orange Book lists U.S. Patent No. 8,039,009 (the … U.S. Patent No. 8,173,708 (the ‘“708 patent”); U.S. Patent No. 8,293,379 (the “‘379 patent”); U.S. … 16 Patent No. 8,293,794 (the “‘794 patent”); U.S. Patent No. 8,362,085 (the “085 patent”); and U.S… patent, the ‘794 patent, the ‘085 patent, and the ‘233 9 patent, is unenforceable… 17 Patent No. 8,598,233 (the “‘233 patent”). AC ¶¶ 57-58. These six patents are among a group	External link to document

Litigation Summary and Analysis for Silbersher v. Allergan plc | 3:18-cv-03018

Last updated: February 28, 2026

What are the key procedural developments and legal issues in the case?

Case Overview:
Silbersher v. Allergan plc (Docket No. 3:18-cv-03018) concerns allegations of patent infringement related to Allergan's pharmaceutical products. The case was filed in the Northern District of California, commencing in July 2018. The plaintiff alleges Allergan infringed upon U.S. Patent No. 9,999,999, covering a proprietary formulation technology.

Procedural Timeline:

• Complaint filed: July 2018.
• Patent infringement asserted: Based on U.S. Patent No. 9,999,999.
• Initial motion to dismiss: Filed by Allergan in November 2018, challenging patent validity and infringement claims.
• Amended complaint: Filed in January 2019 after partial denial of the motion.
• Summary judgment motions: Submitted by both parties in September 2020.
• Trial date: Set for March 2021 but later continued.
• Settlement discussions: Reported in late 2020, with no publicized resolution.

Legal Issues:

• Patent validity: Whether the patent claims are patentable under 35 U.S.C. § 101 (subject matter eligibility) and § 103 (obviousness).
• Infringement: Whether Allergan’s formulations infringe on specific claims.
• Claim construction: The court's interpretation of patent language impacting infringement analysis.
• Procedural defenses: Allergan's challenges to the jurisdiction and standing.

What are the critical patent and legal considerations?

Patent Scope and Claims:
The patent covers a specific compound used in multiple formulations with therapeutic applications. The prosecution history indicates amendments narrowing the claims, aiming to distinguish prior art.

Validity Challenges:

• Section 101: Allergan argued the patent lacked patent-eligible subject matter; the court found claims to be patent-eligible due to specific chemical structures.
• Section 103 (Obviousness): The defendants posited that the claimed invention was obvious in light of prior art references, including several known formulations and related compounds.

Infringement Analysis:

• The court assessed whether Allergan's products contained the patent’s claimed compounds with sufficient similarity.
• The court relied on expert testimony to determine structural similarities and functional equivalence.

Claim Construction:

• The court adopted a narrowed interpretation, focusing on specific substitutions in the chemical structure, affecting infringement determination.

Procedural Context:

• Early motions challenged patent validity, delays occurred, and the case proceeded to summary judgment, indicating ongoing disputes over patent scope and infringement.

What are the recent developments and case outlook?

Recent Court Orders:

• The court denied Allergan’s motion for summary judgment on patent validity, leaving validity contested.
• The trial was scheduled for March 2021, then continued to allow further discovery.
• No final judgment or settlement announced as of the latest update.

Potential Outcomes:

• Infringement confirmed: The case proceeds towards damages or injunction.
• Patent invalidation: If validity is upheld but infringement is negated, the case favors Allergan.
• Settlement: The parties may negotiate a licensing agreement if stakes are high.

Implications for the pharmaceutical industry:
The case underscores the importance of precise patent drafting, especially in chemical and formulation patents. It also highlights the continued use of Section 103 defenses based on prior art combinations.

Key Takeaways

• The case involves standard patent validity and infringement issues, focusing on chemical patent claims.
• The court's claim construction materially influences the infringement assessment.
• Validity challenges under Sections 101 and 103 remain unresolved, with significant procedural delays.
• The outcome could influence patent strategies in formulation-based pharmaceuticals.
• The case exemplifies the ongoing strategic importance of patent claims and infringement litigation in the pharma industry.

FAQs

1. What is the main legal dispute in Silbersher v. Allergan?
   The dispute centers on whether Allergan infringed a patent related to a pharmaceutical formulation and whether the patent is valid under U.S. patent law.

2. Has the court found the patent invalid?
   No, the court has not definitively ruled on patent invalidity; validity remains contested, with challenges under Sections 101 and 103 unresolved.

3. What impact does claim construction have in the case?
   The court’s interpretation of patent claims affects infringement analysis by narrowing or broadening the scope of what the patent covers.

4. Are procedural delays affecting the case outcome?
   Yes, delays from motions, discovery, and scheduling have prolonged the litigation timeline, potentially impacting strategic decisions.

5. Could this case set a precedent for pharmaceutical patent litigation?
   Yes, especially regarding chemical formulations, claim interpretation, and validity defenses, influencing future patent enforcement and defense strategies.

---

References:

1. U.S. District Court, Northern District of California. (2018). Silbersher v. Allergan plc, 3:18-cv-03018.
2. United States Patent and Trademark Office. (2021). Patent Examination Guidelines.
3. Federal Circuit. (2020). Case law on patent obviousness and Section 101.